The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas

Clinical Endocrinology

Volumn 69, Issue 4, 2008, Pages 580-586

  Taieb D ^a   Tessonnier, L ^a   Sebag, F ^a   Niccoli Sire, P ^a   Morange, I ^a   Colavolpe, C ^a   De Micco, C ^b   Barlier, A ^c   Palazzo, F F ^a   Henry, J F ^a   Mundler, O ^a  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPA F 18; FLUORODEOXYGLUCOSE F 18; IASODOPA; PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER STAGING; CHROMAFFIN SYSTEM; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE CANCER; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; VON HIPPEL LINDAU DISEASE; ADRENAL TUMOR; CHEMISTRY; COMPARATIVE STUDY; DISEASE COURSE; EVALUATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; AGED; DIHYDROXYPHENYLALANINE; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 51649127716     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03257.x     Document Type: Article

References (34)

1. Neumann, H.P., Bausch, B., McWhinney, S.R., Bender, B.U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., Januszewicz, A., Eng, C., Smith, W.M., Munk, R., Manz, T., Glaesker, S., Apel, T.W., Treier, M., Reineke, M., Walz, M.K., Hoang-Vu, C., Brauckhoff, M., Klein-Franke, A., Klose, P., Schmidt, H., Maier-Woelfle, M., Peczkowska, M., Szmigielski, C. Eng, C. (2002) Germ-line mutations in nonsyndromic phaeochromocytoma. New England Journal of Medicine, 346, 1459 1466.
2. Gimenez-Roqueplo, A.P., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Khau Van Kien, P., Corvol, P., Plouin, P.F. Jeunemaitre, X. (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research, 63, 5615 5621.
3. Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S.R., Gimenez-Roqueplo, A.P., Grossman, A.B., Kimura, N., Mannelli, M., McNicol, A.M. Tischler, A.S. (2007) Phaeochromocytoma: recommendations for clinical practice from the First International Symposium October 2005. Nature Clinical Practice Endocrinology and Metabolism, 3, 92 102.
4. Timmers, H.J., Kozupa, A., Chen, C.C., Carrasquillo, J.A., Ling, A., Eisenhofer, G., Adams, K.T., Solis, D., Lenders, J.W. Pacak, K. (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated phaeochromocytoma and paraganglioma. Journal of Clinical Oncology, 25, 2262 2269.
5. Shulkin, B.L., Thompson, N.W., Shapiro, B., Francis, I.R. Sisson, J.C. (1999) Phaeochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET. Radiology, 212, 35 41.
6. 18F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology, 220, 373 380.
7. Becherer, A., Szabo, M., Karanikas, G., Wunderbaldinger, P., Angelberger, P., Raderer, M., Kurtaran, A., Dudczak, R. Kletter, K. (2004) Imaging of advanced neuroendocrine tumors with (18) F-FDOPA PET. Journal of Nuclear Medicine, 45, 1161 1167.
8. Montravers, F., Grahek, D., Kerrou, K., Ruszniewski, P., de Beco, V., Aide, N., Gutman, F., Grange, J.D., Lotz, J.P. Talbot, J.N. (2006) Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? Journal of Nuclear Medicine, 47, 1455 1462.
9. 18F-DOPA positron emission tomography for the detection of glomus tumours. European Journal of Nuclear Medicine and Molecular Imaging, 30, 689 694.
10. 18F DOPA whole body PET - initial results. Radiology, 222, 507 512.
11. Mackenzie, I.S., Gurnell, M., Balan, K.K., Simpson, H., Chatterjee, K. Brown, M.J. (2007) The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. European Journal of Endocrinology, 157, 533 537.
12. Brink, I., Hoegerle, S., Klisch, J. Bley, T.A. (2005) Imaging of phaeochromocytoma and paraganglioma. Familial Cancer, 4, 61 68.
13. Brink, I., Schaefer, O., Walz, M. Neumann, H.P. (2006) Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clinical Nuclear Medicine, 31, 39 41.
14. Novosel, A., Heger, A., Lohse, P. Schmidt, H. (2004) Multiple phaeochromocytomas and paragangliomas in a young patient carrying a SDHD gene mutation. European Journal of Pediatrics, 163, 701 703.
15. Takayama, M., Konishi, K., Kishimoto, C., Kanazawa, A. Yamane, H. (2004) A case of cervical paraganglioma: usefulness of FDG PET imaging and a possibility of rare origination. Acta Otolaryngologica Suppl, 554, 81 85.
16. Pacak, K., Eisenhofer, G., Carrasquillo, J.A., Chen, C.C., Whatley, M. Goldstein, D.S. (2002) Diagnostic localization of phaeochromocytoma: the coming of age of positron emission tomography. Annals of the New York Academy of Science, 970, 170 176.
17. 18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected phaeochromocytoma. Annals of Surgical Oncology, 13, 187 197.
18. Ezuddin, S. Fragkaki, C. (2005) MIBG and FDG PET findings in a patient with malignant phaeochromocytoma: a significant discrepancy. Clinical Nuclear Medicine, 30, 579 581.
19. Shulkin, B.L., Koeppe, R.A., Francis, I.R., Deeb, G.M., Lloyd, R.V. Thompson, N.W. (1993) Phaeochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Radiology, 186, 711 715.
20. 123I]-metaiodobenzylguanidine-negative metastatic phaeochromocytoma sites. Nuclear Medicine Communications, 27, 31 36.
21. Fukuchi, K., Inenaga, T., Suzuki, Y., Horita, Y., Hayashida, K. Ishida, Y. (2001) Paraganglioma seen with FDG dual-head γ-camera coincidence imaging after false-negative results of I-123 MIBG imaging. Clinical Nuclear Medicine, 26, 966 967.
22. Chrisoulidou, A., Kaltsas, G., Ilias, I. Grossman, A.B. (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine-Related Cancer, 14, 569 585.
23. Zapanti, E. Ilias, I. (2006) Phaeochromocytoma: physiopathologic implications and diagnostic evaluation. Annals of New York Academy of Science, 1088, 346 360.
24. Ilias, I. Pacak, K. (2005) Diagnosis and management of tumors of the adrenal medulla. Hormone and Metabolic Research, 37, 717 721.
25. Ilias, I., Sahdev, A., Reznek, R.H., Grossman, A.B. Pacak, K. (2007) The optimal imaging of adrenal tumours: a comparison of different methods. Endocrine-Related Cancer, 14, 587 599.
26. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. Journal of Nuclear Medicine, 42, 1795 1799.
27. 18F-FDG PET/CT in the evaluation of adrenal masses. Journal of Nuclear Medicine, 47, 32 37.
28. 18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism, 91, 2665 2671.
29. Leboulleux, S., Dromain, C., Bonniaud, G., Auperin, A., Caillou, B., Lumbroso, J., Sigal, R., Baudin, E. Schlumberger, M. (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. Journal of Clinical Endocrinology and Metabolism, 91, 920 925.
30. Modica-Napolitano, J.S., Kulawiec, M. Singh, K.K. (2007) Mitochondria and human cancer. Current Molecular Medicine, 7, 121 131.
31. Pelicano, H., Du Xu, R.H.M., Feng, L., Sasaki, R., Carew, J.S., Hu, Y., Ramdas, L., Hu, L., Keating, M.J., Zhang, W., Plunkett, W. Huang, P. (2006) Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. Journal of Cell Biology, 175, 913 923.
32. -, oxidative stress, and genomic instability. Cancer Research, 66, 7615 7620.
33. 123I-MIBG SPECT: a study of patients being evaluated for phaeochromocytoma. Journal of Nuclear Medicine, 48, 1077 1083.
34. Dallner, O.S., Chernogubova, E., Brolinson, K.A. Bengtsson, T. (2006) β3-adrenergic receptors stimulate glucose uptake in brown adipocytes by two mechanisms independently of glucose transporter 4 translocation. Endocrinology, 147, 5730 5739.